[1] T.W. Chen, A.R. Razak, P.L. Bedard, L.L. Siu, A.R. Hansen, A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors, Ann. Oncol. 26 (2015) 1824–1829. doi:10.1093/annonc/mdv182.
[2] J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino, et al., Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline, J. Clin. Oncol. 36 (2018) 1714–1768. doi:10.1200/JCO.2017.77.6385.
[3] G. Mazzaschi, F. Facchinetti, G. Missale, D. Canetti, D. Madeddu, A. Zecca, et al., The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC, Lung Cancer. 127 (2019) 153–163. doi:10.1016/j.lungcan.2018.11.038.
[4] J.I. Youn, S.M. Park, S. Park, G. Kim, H.J. Lee, J. Son, et al., Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer, Sci. Rep. 10 (2020) 1–7. doi:10.1038/s41598-020-65666-x.
[5] L. Chen, D.B. Flies, Molecular mechanisms of T cell co-stimulation and co-inhibition, Nat. Rev. Immunol. 13 (2013) 227–242. doi:10.1038/nri3405.
[6] J. Bourque, D. Hawiger, Immunomodulatory bonds of the partnership between dendritic cells and T cells, 2018. doi:10.1615/CritRevImmunol.2018026790.
[7] B. Reizis, Plasmacytoid Dendritic Cells: Development, Regulation, and Function, Immunity. 50 (2019) 37–50. doi:10.1016/j.immuni.2018.12.027.
[8] J.L. Karnell, Y. Wu, N. Mittereder, M.A. Smith, M. Gunsior, L. Yan, et al., Depleting plasmacytoid dendritic cells reduces local type i interferon responses and disease activity in patients with cutaneous lupus, Sci. Transl. Med. 13 (2021) 1–14. doi:10.1126/scitranslmed.abf8442.
[9] S. Caielli, S. Athale, B. Domic, E. Murat, M. Chandra, R. Banchereau, et al., Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus, J. Exp. Med. 213 (2016) 697–713. doi:10.1084/jem.20151876.
[10] L. van Bon, A.J. Affandi, J. Broen, R.B. Christmann, R.J. Marijnissen, L. Stawski, et al., Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis, N. Engl. J. Med. 370 (2014) 433–443. doi:10.1056/nejmoa1114576.
[11] F.O. Nestle, C. Conrad, A. Tun-Kyi, B. Homey, M. Gombert, O. Boyman, et al., Plasmacytoid predendritic cells initiate psoriasis through interferon-α production, J. Exp. Med. 202 (2005) 135–143. doi:10.1084/jem.20050500.
[12] D.C. Baumgart, D. Metzke, O. Guckelberger, A. Pascher, C. Grötzinger, I. Przesdzing, et al., Aberrant plasmacytoid dendritic cell distribution and function in patients with Crohn’s disease and ulcerative colitis, Clin. Exp. Immunol. 166 (2011) 46–54. doi:10.1111/j.1365-2249.2011.04439.x.
[13] S. Leskela, A. Rodríguez-Muñoz, H. De La Fuente, N. Figueroa-Vega, P. Bonay, P. Martín, et al., Plasmacytoid dendritic cells in patients with autoimmune thyroid disease, J. Clin. Endocrinol. Metab. 98 (2013) 2822–2833. doi:10.1210/jc.2013-1273.
[14] K. Minaga, T. Watanabe, A. Hara, T. Yoshikawa, K. Kamata, M. Kudo, Plasmacytoid Dendritic Cells as a New Therapeutic Target for Autoimmune Pancreatitis and IgG4-Related Disease, Front. Immunol. 12 (2021) 1–8. doi:10.3389/fimmu.2021.713779.
[15] J.S. Allen, K. Pang, A. Skowera, R. Ellis, C. Rackham, B. Lozanoska-Ochser, et al., Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture, Diabetes. 58 (2009) 138–145. doi:10.2337/db08-0964.
[16] B. Cederblad, S. Blomberg, H. Vallin, A. Perers, G. V. Alm, L. Rönnblom, Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells, J. Autoimmun. 11 (1998) 465–470. doi:10.1006/jaut.1998.0215.
[17] L. Farkas, K. Beiske, F. Lund-Johansen, P. Brandtzaeg, F.L. Jahnsen, Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions, Am. J. Pathol. 159 (2001) 237–243. doi:10.1016/S0002-9440(10)61689-6.
[18] J.I. Youn, S.M. Park, S. Park, G. Kim, H.J. Lee, J. Son, et al., Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer, Sci. Rep. 10 (2020) 1–7. doi:10.1038/s41598-020-65666-x.
[19] J. Hsu, D.H. Raulet, M. Ardolino, J. Hsu, J.J. Hodgins, M. Marathe, et al., Contribution of NK cells to immunotherapy mediated by PD-1 / PD-L1 blockade Graphical abstract Find the latest version : Contribution of NK cells to immunotherapy mediated by PD-1 / PD-L1 blockade, J. Clin. Invest. 128 (2018) 4654–4668.